Ed Silverman, who now is a special writer for The Wall Street Journal, sent out the following announcement on Wednesday:
I’m happy to introduce the latest iteration of the Pharmalot blog.
After a brief hiatus, Pharmalot has found a new home with The Wall Street Journal as part of its ongoing commitment to provide must-read coverage of the pharmaceutical industry.
Readers can expect to see a rich menu of blog posts about the fast-moving and complicated world that develops and markets medicines. The long-standing mission will be familiar – to offer a breezy mix of news and analysis of the pharmaceutical industry, as well as an opportunity to discuss events and issues.
As before, the blog will strive to run items that add depth to reader understanding of an industry in flux – from exclusive stories and incremental tidbits to question-and-answer interviews with prominent players and reader polls about key matters.
And the subject matter will continue to touch on many topical bases – successes and failures as told by executives and patients; R&D challenges; patent skirmishes; marketing wars; government oversight; the use of social media and pricing tussles with payers, to name a few.
We would be remiss, however, if we did not note that we will also build on the efforts of the former WSJ Health Blog that once occupied this space. In fact, some of the same writers who contributed to that endeavor, along with other members of the WSJ pharma team, will show up here from time to time.
So grab a cup of stimulation – or perhaps a bottle of water, if you prefer – and dig in as we begin anew. Don’t forget to follow us on Twitter – @pharmalot.
